The Lung Cancer Channel is supported with funding from Johnson & Johnson (Gold) and Takeda (Gold).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ELCC 2021 | Patterns of relapse after radiotherapy in SCLC and future treatment strategies
Sanjay Popat, BSc, MBBS, FRCP, PhD, The Royal Marsden NHS Foundation Trust, London, UK, discusses the findings of a subset analysis of the CONVERT trial (NCT00433563) investigating patterns of relapse following thoracic radiotherapy in patients with limited-stage small cell lung cancer (SCLC). The CONVERT trial is a randomized trial comparing once daily versus twice daily radiotherapy for limited stage SCLC. Prof. Popat discusses how outcomes can be improved for patients with limited-stage SCLC, such as by increasing local control or by increasing the dose in hypofractionated radiotherapy, and the potential role of immune checkpoint inhibitors, highlighting data from the ADRIATIC trial (NCT03703297) and the NRG-LU005 trial (NCT03811002). This video was recorded at the virtual European Lung Cancer Congress (ELCC) 2021.
